Redeye embraces BONESUPPORT’s indication-broadening to spinal fusion communicated on the CMD. While conservatively approached, we include its new venture into spine to our financial models. Moreover, the presentation and chat with management strengthened our confidence in a continuous strong sales growth in EUROW. We raise our fair value range considerably and point to several key catalysts during next year that should push the share towards our new base case.